Lutetium (177 lu) vipivotide tetraxetan

Pluvicto

1000 MBq / ML SolutionCanadaMarketedAuthorised 7 Nov 2022

Open in the registerAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

PluvictoEuropean Union · Novartis Europharm LimitedSame brand
PluvictoCroatiaSame brand
PluvictoItaly · Soluzione iniettabile o per infusione · Novartis Europharm LimitedSame brand
Pluvicto 1.000 MBq/ml oplossing voor injectie/infusieNetherlands · Oplossing voor injectie of infusie · Novartis Europharm LimitedSame brand
PLUVICTO SOLUTION FOR INJECTION/INFUSION 1000 MBq/mLSingapore · 1000 MBq/mL · injection, solution (radiopharmaceutical) · Novartis (Singapore) Pte LTDSame brand

Documents

The official texts, at the regulator.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Lutetium (177 lu) vipivotide tetraxetan

Pluvicto

1000 MBq / ML SolutionCanadaMarketedAuthorised 7 Nov 2022

Open in the registerAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Documents

The official texts, at the regulator.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Register entryHealth Canada

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Health Canada, Canada

Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.

Licence: Open Government Licence Canada · Added 13 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Lutetium (177 lu) vipivotide tetraxetan
Strength: 1000 MBq / ML
Dosage form: Solution
Route: Intravenous
Register: Canada (Health Canada)
Status: Marketed
Authorised: 7 Nov 2022
Registration: DIN 02530198
Marketing authorisation holder: Novartis Pharmaceuticals Canada INC
ATC code: V10XX05
Group: Various
Supply: SCHEDULE C